Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Youri Glupczynski is active.

Publication


Featured researches published by Youri Glupczynski.


Clinical Microbiology and Infection | 2012

Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe

Rafael Cantón; Murat Akova; Yehuda Carmeli; Christian G. Giske; Youri Glupczynski; Marek Gniadkowski; David M. Livermore; Vivi Miriagou; Thierry Naas; Gian Maria Rossolini; Ørjan Samuelsen; Harald Seifert; Neil Woodford; Patrice Nordmann

Plasmid-acquired carbapenemases in Enterobacteriaceae, which were first discovered in Europe in the 1990s, are now increasingly being identified at an alarming rate. Although their hydrolysis spectrum may vary, they hydrolyse most β-lactams, including carbapenems. They are mostly of the KPC, VIM, NDM and OXA-48 types. Their prevalence in Europe as reported in 2011 varies significantly from high (Greece and Italy) to low (Nordic countries). The types of carbapenemase vary among countries, partially depending on the cultural/population exchange relationship between the European countries and the possible reservoirs of each carbapenemase. Carbapenemase producers are mainly identified among Klebsiella pneumoniae and Escherichia coli, and still mostly in hospital settings and rarely in the community. Although important nosocomial outbreaks with carbapenemase-producing Enterobacteriaceae have been extensively reported, many new cases are still related to importation from a foreign country. Rapid identification of colonized or infected patients and screening of carriers is possible, and will probably be effective for prevention of a scenario of endemicity, as now reported for extended-spectrum β-lactamase (mainly CTX-M) producers in all European countries.


Antimicrobial Agents and Chemotherapy | 1999

Aminoglycosides: Activity and Resistance

Marie-Paule Mingeot-Leclercq; Youri Glupczynski; Paul M. Tulkens

Aminoglycosides are highly potent, broad-spectrum antibiotics with many desirable properties for the treatment of life-threatening infections ([28][1]). Their history begins in 1944 with streptomycin and was thereafter marked by the successive introduction of a series of milestone compounds (


Gut | 2012

Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption

Francis Mégraud; Samuel Coenen; Ann Versporten; Manfred Kist; Manuel Lopez-Brea; Alexander M. Hirschl; Leif P. Andersen; Herman Goossens; Youri Glupczynski

Objective Resistance to antibiotics is the major cause of treatment failure of Helicobacter pylori infection. A study was conducted to assess prospectively the antibacterial resistance rates of H pylori in Europe and to study the link between outpatient antibiotic use and resistance levels in different countries. Design Primary antibiotic resistance rates of H pylori were determined from April 2008 to June 2009 in 18 European countries. Data on yearly and cumulative use over several years of systemic antibacterial agents in ambulatory care for the period 2001–8 were expressed in Defined Daily Doses (DDD) per 1000 inhabitants per day. The fit of models and the degree of ecological association between antibiotic use and resistance data were assessed using generalised linear mixed models. Results Of 2204 patients included, H pylori resistance rates for adults were 17.5% for clarithromycin, 14.1% for levofloxacin and 34.9% for metronidazole, and were significantly higher for clarithromycin and levofloxacin in Western/Central and Southern Europe (>20%) than in Northern European countries (<10%). Model fit improved for each additional year of antibiotic use accumulated, but the best fit was obtained for 2005. A significant association was found between outpatient quinolone use and the proportion of levofloxacin resistance (p=0.0013) and between the use of long-acting macrolides only and clarithromycin resistance (p=0.036). Conclusion In many countries the high rate of clarithromycin resistance no longer allows its empirical use in standard anti-H pylori regimens. The knowledge of outpatient antibiotic consumption may provide a simple tool to predict the susceptibility of H pylori to quinolones and to macrolides and to adapt the treatment strategies.


European Journal of Clinical Microbiology & Infectious Diseases | 2001

European Multicentre Survey of in Vitro Antimicrobial Resistance in Helicobacter pylori

Youri Glupczynski; Francis Mégraud; López-Brea M; Leif P. Andersen

Abstract. A multicentre in vitro survey was carried out in 1998 in 22 European centres in order to assess the variation in the prevalence of Helicobacter pylori resistance. The susceptibility of 1,274 isolates to metronidazole, clarithromycin and amoxicillin was determined by the E test. The mean rate of resistance to metronidazole was 33.1% (95% CI, 7.5–58.9), to clarithromycin 9.9% (95% CI, 0–28.1) and to amoxicillin 0.8% (95% CI, 0–8.9). Resistance to metronidazole was significantly higher in females (P<0.001), while resistance to clarithromycin was significantly higher in children and teens (P<0.05). Resistance to both agents also tended to be higher in strains isolated from patients from southern European countries than in those isolated from patients from central or northern Europe. Overall, these results emphasize the need for further surveys of Helicobacter pylori sensitivity to antibiotics at a national and regional level.


Eurosurveillance | 2013

Carbapenemase-producing Enterobacteriaceae in Europe: A survey among national experts from 39 countries, February 2013

Corinna Glasner; Barbara Albiger; Girbe Buist; A. Tambić Andrašević; Rafael Cantón; Yehuda Carmeli; Alexander W. Friedrich; Christian G. Giske; Youri Glupczynski; Marek Gniadkowski; David M. Livermore; Patrice Nordmann; Laurent Poirel; Gian Maria Rossolini; Harald Seifert; Alkiviadis Vatopoulos; Timothy R. Walsh; Neil Woodford; Tjibbe Donker; Dominique L. Monnet; Hajo Grundmann

The spread of carbapenemase-producing Enterobacteriaceae (CPE) is a threat to healthcare delivery, although its extent differs substantially from country to country. In February 2013, national experts from 39 European countries were invited to self-assess the current epidemiological situation of CPE in their country. Information about national management of CPE was also reported. The results highlight the urgent need for a coordinated European effort on early diagnosis, active surveillance, and guidance on infection control measures.


Antimicrobial Agents and Chemotherapy | 2001

Accurate Prediction of Macrolide Resistance in Helicobacter pylori by a PCR Line Probe Assay for Detection of Mutations in the 23S rRNA Gene: Multicenter Validation Study

Leen-Jan van Doorn; Youri Glupczynski; Johannes G. Kusters; Francis Mégraud; Peter Midolo; Nadia Maggi-Solcà; Dulciene Maria Magalhães Queiroz; Nathalie Nouhan; Els Stet; Wim Quint

ABSTRACT Helicobacter pylori strains from 299 patients were tested in six laboratories in different countries. Macrolide susceptibility of the strains was determined by agar dilution (17.4%) or the epsilometer test (82.6%). Mutations in the 23S ribosomal DNA (rDNA) that are associated with macrolide resistance were analyzed by PCR and reverse hybridization (PCR-line probe assay [LiPA]). This method identifies A2115G, G2141A, A2142G, A2142C, A2142T, A2143G, and A2143C mutations in the 23S rDNA. vacA s-region (s1a, s1b, s1c, and s2) and m-region (m1, m2a, and m2b) genotypes andcagA status were also determined using another PCR-LiPA system. Of the 299 strains investigated by MIC testing, 130 (43.5%) were resistant and 169 (56.5%) were susceptible to clarithromycin. Of the 130 resistant strains, 127 (97.7%) contained 23S rDNA mutations, whereas 167 (98.8%) of the 169 susceptible strains contained wild-type sequences. The predominant mutations were A2143G (45.2%) and A2142G (33.3%). Twenty-eight (19.8%) strains contained multiple 23S rDNA mutations. Only five resistant strains contained the A2142C mutation (three of these in combination with the A2142G mutation), and the A2115G, G2141A, A2142T, and A2143C mutations were not found. MICs of clarithromycin for the A2142G mutant strains were significantly higher than MICs for the A2143G strains. Although there was no significant association between 23S rDNA mutations and the vacA andcagA status, clarithromycin-susceptible strains more often contained mixed vacA genotypes, indicating the presence of multiple H. pylori strains. In conclusion, our data confirmed the very strong association between 23S rDNA mutations and macrolide resistance and showed that the PCR-LiPA permits accurate and reliable diagnosis of macrolide resistance in H. pylori.


Journal of Antimicrobial Chemotherapy | 2006

Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria.

Ingrid Wybo; Denis Piérard; Inge Verschraegen; Marijke Reynders; Kristof Vandoorslaer; Geert Claeys; Michel Delmée; Youri Glupczynski; B. Gordts; Margaretha Ieven; Pierrette Melin; Marc Struelens; Jan Verhaegen; Sabine Lauwers

OBJECTIVES To collect recent data on the susceptibility of anaerobes and to compare them with results from previous studies. METHODS Four hundred and forty-three anaerobic clinical isolates from various body sites were prospectively collected from October 2003 to February 2005 in nine Belgian hospitals. MICs were determined for nine anti-anaerobic and three recently developed antibiotics. RESULTS Most gram-negative bacilli except Fusobacterium spp. were resistant to penicillin. Piperacillin/tazobactam, metronidazole, chloramphenicol, meropenem and amoxicillin/clavulanic acid were very active against all groups, but only 86% of Bacteroides fragilis group strains were susceptible to the latter. Cefoxitin, cefotetan and clindamycin were less active. In particular, only 62%, 52% and 48% of B. fragilis group strains were susceptible, respectively. Clindamycin shows a continuing decrease in activity, as 83% were still susceptible in 1987 and 66% in 1993-94. Anti-anaerobic activity of the new antibiotics is interesting, with MIC50 and MIC90 of 1 and >32 mg/L for moxifloxacin, 2 and 4 mg/L for linezolid and 0.5 and 8 mg/L for tigecycline. CONCLUSIONS The susceptibility of anaerobic bacteria remains stable in Belgium, except for clindamycin, which shows a continuous decrease in activity. However, for each of the tested antibiotics, at least a few resistant organisms were detected. Consequently, for severe infections involving anaerobic bacteria, it could be advisable to perform microbiological testing instead of relying on known susceptibility profiles. Periodically monitoring background susceptibility remains necessary to guide empirical therapy.


Journal of Clinical Microbiology | 2011

Evaluation of a DNA microarray (Check-MDR CT102) for rapid detection of TEM, SHV, and CTX-M extended-spectrum β-lactamases and of KPC, OXA-48, VIM, IMP, and NDM-1 carbapenemases.

Thierry Naas; Gaelle Cuzon; Pierre Bogaerts; Youri Glupczynski; Patrice Nordmann

ABSTRACT The Check-MDR CT102 microarray, aimed at identifying bacteria producing extended-spectrum β-lactamase (ESBL) (SHV, TEM, and CTX-M) and carbapenemase (KPC, OXA-48, VIM, IMP, and NDM-1), was evaluated on a total of 144 Gram-negative strains expressing various β-lactamases. The sensitivity and specificity were 100% for most tested genes, suggesting that this assay allows accurate identification of common ESBL and carbapenemase producers from bacterial cultures.


Lancet Infectious Diseases | 2010

Global spread of New Delhi metallo-β-lactamase 1

Pierre Bogaerts; Alexia Verroken; Béatrice Jans; Olivier Denis; Youri Glupczynski

www.thelancet.com/infection Vol 10 December 2010 831 3 Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10: 597–602. 4 Tängdén T, Cars O, Melhus Ǻ, Löwdin E. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum β-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother 2010; 54: 3564–68. 5 Cohen Stuart J, Leverstein-Van Hall MA, for the Dutch Working Party on the Detection of Highly Resistant Microorganisms. Guideline for phenotypic screening and confi rmation of carbapenemases in Enterobacteriaceae. Int J Antimicrob Agents 2010; 36: 205–10.


Journal of Clinical Microbiology | 2010

Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of Nocardia species.

Alexia Verroken; Michèle Janssens; Catherine Berhin; Pierre Bogaerts; Te-Din Huang; Georges Wauters; Youri Glupczynski

ABSTRACT The identification of Nocardia species, usually based on biochemical tests together with phenotypic in vitro susceptibility and resistance patterns, is a difficult and lengthy process owing to the slow growth and limited reactivity of these bacteria. In this study, a panel of 153 clinical and reference strains of Nocardia spp., altogether representing 19 different species, were characterized by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). As reference methods for species identification, full-length 16S rRNA gene sequencing and phenotypical biochemical and enzymatic tests were used. In a first step, a complementary homemade reference database was established by the analysis of 110 Nocardia isolates (pretreated with 30 min of boiling and extraction) in the MALDI BioTyper software according to the manufacturers recommendations for microflex measurement (Bruker Daltonik GmbH, Leipzig, Germany), generating a dendrogram with species-specific cluster patterns. In a second step, the MALDI BioTyper database and the generated database were challenged with 43 blind-coded clinical isolates of Nocardia spp. Following addition of the homemade database in the BioTyper software, MALDI-TOF MS provided reliable identification to the species level for five species of which more than a single isolate was analyzed. Correct identification was achieved for 38 of the 43 isolates (88%), including 34 strains identified to the species level and 4 strains identified to the genus level according to the manufacturers log score specifications. These data suggest that MALDI-TOF MS has potential for use as a rapid (<1 h) and reliable method for the identification of Nocardia species without any substantial costs for consumables.

Collaboration


Dive into the Youri Glupczynski's collaboration.

Top Co-Authors

Avatar

Pierre Bogaerts

Université catholique de Louvain

View shared research outputs
Top Co-Authors

Avatar

Te-Din Huang

Cliniques Universitaires Saint-Luc

View shared research outputs
Top Co-Authors

Avatar

Ariane Deplano

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Catherine Berhin

Université catholique de Louvain

View shared research outputs
Top Co-Authors

Avatar

Olivier Denis

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Thierry Naas

Université Paris-Saclay

View shared research outputs
Top Co-Authors

Avatar

Paul M. Tulkens

Université catholique de Louvain

View shared research outputs
Top Co-Authors

Avatar

Caroline Bauraing

Université catholique de Louvain

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michel Delmée

Université catholique de Louvain

View shared research outputs
Researchain Logo
Decentralizing Knowledge